High-throughput nanoMEA-based Proarrhythmia Assay

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44HL131169-02A1
Agency Tracking Number: R44HL131169
Amount: $1,748,863.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA18-837
Timeline
Solicitation Year: 2018
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-25
Award End Date (Contract End Date): 2020-06-30
Small Business Information
13757 26TH AVE NE, Seattle, WA, 98125-3417
DUNS: 079748388
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 NICHOLAS GEISSE
 (800) 913-4403
 nick@nanosurfacebio.com
Business Contact
 ELLIOT FISHER
Phone: (800) 913-4403
Email: nanosurfacebio15@gmail.com
Research Institution
N/A
Abstract
PROJECT SUMMARY Failure of new drugs at late stages of development is an extremely costly event commonly associated with the detection of unexpected arrhythmogenic properties in novel drugs Undetected arrhythmia inducing effects are also a common reason for drug withdrawal from the market As a result the FDA now mandates that all new drugs be tested for potential arrhythmogenic properties which has led to a growing market for accurate and cost effective preclinical screening tools Human pluripotent stem cell derived cardiomyocytes hPSC CMs offer the means to generate superior in vitro cardiac tissues for such applications However an inability for hPSC CMs to develop into adequate representations of adult myocardial tissue under standard culture conditions is a major impediment to the use of such cell constructs in effective preclinical screening protocols Generation of mature cardiac tissues that accurately recapitulate the form and function of the adult human heart is necessary to provide preclinical data capable of reliably predicting a compound s efficacy and or toxicity when transferred to a clinical setting Our Phase SBIR project demonstrated that nanopatterned microelectrode arrays nanoMEAs can be used to promote cardiomyocyte maturation to the point where more representative drug responses are achieved Based on results achieved during Phase NanoSurface Biomedical is applying for Phase SBIR funding to further develop and optimize an integrated prototype nanoMEA system to enhance cardiac maturation and high throughput functional analysis for improved drug induced cardiotoxicity screening We hypothesize that the establishment of a well nanoMEA plate will improve cardiac structural and functional development to enable the collection of high throughput compound toxicity data with greater predictive capacity To test these hypotheses this grant renewal will focus on the validation of our optimized high throughput nanoMEA plate design including the establishment of custom built hardware and software to facilitate rapid data analysis as well as development of key biological metrics for device validation Aim We will then use this platform to investigate the ability for hPSC CMs to generate functional responses to known arrhythmogenic compounds that are representative of these drugs activity in vivo Aim Cell line variability will also be investigated to understand how genotypic differences translate into functional variance in vitro Lastly the capacity for nanopatterned MEAs to promote the development of disease phenotypes in hPSC CMs from structural cardiomyopathy patients will be investigated as a means to broaden the utility of our eventual product The structural impact of nanopatterns on cardiomyocytes provides strong rationale for the ability for these topographic substrates to help stratify disease phenotypes from wild type controls and represents a second substantial market for this technology Successful validation of our high throughput nanopatterned MEA system will produce an innovative new product designed specifically to relieve critical deficiencies and reduce cost in the current preclinical drug development process PROJECT NARRATIVE We will develop a well nanopatterned microelectrode array capable of promoting and measuring the functional development of mature human cardiac tissue in a controlled laboratory setting Such a system will enable more accurate and predictive screening of drug effects on human cardiac performance prior to their advancement to human trials In turn this will streamline drug development protocols leading to shorter development times and bringing new life saving drugs to the market more quickly

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government